Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $105M | $39M | $47M | $79M | $47M | $73M | $34M | $3M | $0M |
| Beneficio bruto | — | $39M | $47M | $79M | $47M | $73M | $34M | $2M | $0M |
| % de margen bruto | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 71.9% | — |
| Ingresos operativos (EBIT) | ($351M) | ($349M) | ($262M) | ($166M) | ($161M) | ($101M) | ($46M) | ($42M) | ($21M) |
| % de margen operativo | -334.3% | -891.3% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% | — |
| Ingresos netos | ($299M) | ($311M) | ($224M) | ($147M) | ($155M) | ($100M) | ($46M) | ($41M) | ($21M) |
| % de margen neto | -284.8% | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1407.4% | — |
| EBITDA | — | ($303M) | ($216M) | ($143M) | ($152M) | ($98M) | ($44M) | ($40M) | ($21M) |
| Beneficio por acción (EPS) | $-3.30 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.02 | $-0.93 | $-0.48 |
| Acciones en circulación (M) | — | 84M | 75M | 58M | 54M | 48M | 45M | 45M | 45M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de KYMR. /companies/us/KYMR
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms